drugset / Trial / NCT04322578
Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to explore the efficacy and safety of Crizotinb or Standard Chemotherapy in Met exon 14 skipping Advanced Non-small Cell Lung Cancer
Timeline
- Start
- 2020-03-24
- Primary completion
- 2025-03-24
- Completion
- 2026-03-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Crizotinib | Small molecule | 250 mg | Oral |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |
| Subject | Savolitinib | Small molecule | 300 mg | Oral |